Clinical trials: Heparin-induced Thrombocytopenia
Heparin Induced Thrombocytopenia (HIT)
Heparin Induced Thrombocytopenia: Pharmacoeconomics
Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the purposes of this study.
- Trial name
- NCT00456001
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Brigham and Women's Hospital
Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT).
- Trial name
- NCT05785819
- Testing
- VLX-1005
- Where
- 14 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veralox Therapeutics
Heparin-Induced Thrombocytopenia
Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)
The purpose of this study is to test the safety and efficacy of fondaparinux in patients with heparin-induced thrombocytopenia (HIT).
- Trial name
- NCT00603824
- Testing
- fondaparinux, argatroban or lepirudin
- Sponsor
- Methodist Healthcare - Memphis
Heparin-induced Thrombocytopenia
Cangrelor As Treatment for Cardiac Surgery Associated With Heparin Induced Thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is a rare but serious immune complication of heparin exposure that paradoxically increases the risk of thrombosis.
- Trial name
- CATCH-IT (NCT07817680)
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Société Française d'Anesthésie et de Réanimation
Suspected Heparin-Induced Thrombocytopenia
A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
Compare Clinical Success and Costs in two Arms
- Trial name
- HIT (NCT00787332)
- Testing
- Desirudin or Argatroban®
- Where
- 24 sites in United States
- Volunteers
- 16 people
- Sponsor
- Canyon Pharmaceuticals, Inc.
Heparin-Induced Thrombocytopenia
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
The purpose of this study is to determine how safe and effective fondaparinux is in treating patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).
- Trial name
- NCT00673439
- Testing
- fondaparinux, warfarin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Louisville
Heparin-induced Thrombocytopenia
Argatroban Monitoring in Critically Ill Patients: Evaluation of a Novel Ecarin-based Bedside Test
Argatroban is a parenteral direct Thrombininhibitor used for anticoagulation in patients suffering from heparin induced thrombocytopenia (HIT).
- Trial name
- NCT04751357
- Testing
- ECA-Test (Clot-Pro)
- Where
- Austria
- Volunteers
- 21 people
- Sponsor
- Medical University of Vienna
Heparin-induced Thrombocytopenia
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)
- Trial name
- HITSOVA (NCT03809481)
- Testing
- Danaparoid Sodium, Argatroban
- Where
- 35 sites in United States, Bosnia and Herzegovina and 7 more
- Volunteers
- 7 people
- Sponsor
- Aspen Global Incorporated
Deep Venous Thrombosis
Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery
A blood clot in the veins, also known as deep venous thrombosis (DVT), is one of the most common complications after surgery. This may result in death if a clot breaks off and travel to the lungs; this is referred to as pulmonary…
- Trial name
- NCT00329433
- Testing
- Desirudin (Iprivask™), Heparin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Washington University School of Medicine
Heparin, Thrombocytopenia
EMR Tool Impact on HIT Documentation and Management
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction to heparin products which results in a prothrombotic state.
- Conditions
- Heparin, Thrombocytopenia, Electronic Health Records
- Trial name
- NCT05439265
- Testing
- Electronic medical record order panel and resident involvement
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Rush University Medical Center
Heparin-induced Thrombocytopenia (HIT)
Performance Evaluation of the Biological Diagnosis of HIT
Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy with a non-negligible incidence (estimated at 2.6% of unfractionated heparin treatments and 0.2% of low molecular weight heparin treatments).
- Trial name
- HIT (NCT06180785)
- Where
- France
- Volunteers
- 894 people
- Sponsor
- University Hospital, Strasbourg, France